Compare MPLX LP (MPLX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Merck & Co., Inc. — how do they compare? MPLX LP trades at $60.05 (market cap $61.06B), while Merck & Co., Inc. trades at $148.16 (market cap $363.98B). The key difference: Merck & Co., Inc. is far larger — about 6× MPLX LP's market cap, and MPLX LP pays the higher dividend (7.15%). Which is the better fit depends on your goals.
| MPLX | MRK | |
|---|---|---|
Market Cap | $61.06B | $363.98B |
Sector | Technology | Health |
52-Week High | $60.51 | $156.43 |
52-Week Low | $47.80 | $77.60 |
Enterprise Value | $86.17B | $410.75B |
Dividend Yield | 7.15% | 2.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $59.83, up 0.27% today, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong 2025 results with $11.47B revenue and $4.91B net income, though recent quarterly EPS results have missed expectations. A $1.08 dividend is scheduled for August 2026, supporting its income appeal.
The outlook remains positive given analyst buy ratings and growth projects, but risks include rising leverage near 4x and sensitivity to energy market volatility. Earnings consistency in upcoming quarters is critical to sustaining the current valuation and distribution growth trajectory.
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
